Arcus Biosciences Inc. (NYSE:RCUS) saw an upside of 27.17% to $23.92 after adding $5.11on Wednesday. The 5-day average trading volume is 829,381 shares of the company’s common stock. It has gained $25.36 in the past week and touched a new high 4 times within the past 5 days. An average of 667,070 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 916,664.
RCUS’s 1-month performance is 24.07% or $3.96 on its low of $17.25 reached on 08/17/23. The company’s shares have touched a 52-week low of $15.70 and high of $36.13, with the stock’s rally to the 52-week high happening on 08/23/23. YTD, RCUS has achieved 15.67% or $3.32 and has reached a new high 9 times. However, the current price is down -33.79% from the 52-week high price.
Insider Transactions
RCUS stock investors last saw insider trading activity on Jul 28.Jarrett Jennifer (Chief Operating Officer) most recently sold 45,000 shares at $20.25 per share on Jul 28. This transaction cost the insider $911,250. Chief Accounting Officer, Azoy Alexander, sold 1,018 shares at a price of $20.41 on Jul 03. Then, on Jun 22, Chief Operating Officer Jarrett Jennifer sold 12,437 shares at a price of $19.12 per share. This transaction amounted to $237,795.
Valuation Metrics
RCUS stock has a beta of 0.83. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 13.61 while the price-to-book (PB) in the most recent quarter is 3.09.
Arcus Biosciences Inc.’s quick ratio for the period ended June 29 was 5.50, with the current ratio over the same period at 5.50. The trailing 12-month EBITDA margin is -237.50%. The firm’s gross profit as reported stood at $392.0 million against revenue of $112.0 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 11.16% to -$75.0 million, while revenue of -$80.0 million was -6.67% off the previous quarter. Analysts expected RCUS to announce -$1.1 per share in earnings in its latest quarter, but it posted -$1.04, representing a 5.50% surprise. EBITDA for the quarter stood at more than -$85.0 million. Shareholders hold equity totaling $74.5 million.
Let’s look briefly at Arcus Biosciences Inc. (RCUS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 83.36% to suggest the stock is trending Overbought, with historical volatility in this time period at 125.43%.
The stock’s 5-day moving average is $19.69, reflecting a +35.58% or $6.30 change from its current price. RCUS is currently trading +23.45% above its 20-day SMA, +37.45% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +19.34% and SMA200 by-1.52%.
Stochastic %K and %D was 76.99% and 68.23% and the average true range (ATR) pointed at 1.42. The RSI (14) points at 75.19%, while the 14-day stochastic is at 83.21% with the period’s ATR at 1.22. The stock’s 9-day MACD Oscillator is pointing at 1.67 and 1.84 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Arcus Biosciences Inc. (NYSE: RCUS), BofA Securities launched coverage with a Neutral rating. Analysts offering their rating for RCUS stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate RCUS as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 10 have offered a “buy” rating.
What is RCUS’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $21.00 and a high of $70.00, with their median price target at $39.50. Looking at these predictions, the average price target given by analysts is for Arcus Biosciences Inc. (RCUS) stock is $42.67.
